<unk>  (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment. It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval.
Edivoxetine
Vortioxetine
Atomoxetine
Dapoxetine
Nabilone
Fluparoxan
Duloxetine
Pirlindole